These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32432822)

  • 1. Hypoxia-inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36.
    Rey E; Meléndez-Rodríguez F; Marañón P; Gil-Valle M; Carrasco AG; Torres-Capelli M; Chávez S; Del Pozo-Maroto E; Rodríguez de Cía J; Aragonés J; García-Monzón C; González-Rodríguez Á
    Liver Int; 2020 Oct; 40(10):2553-2567. PubMed ID: 32432822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
    J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
    Rada P; González-Rodríguez Á; García-Monzón C; Valverde ÁM
    Cell Death Dis; 2020 Sep; 11(9):802. PubMed ID: 32978374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36.
    Zhu H; Zhao T; Zhao S; Yang S; Jiang K; Li S; Kang Y; Yang Z; Shen J; Shen S; Tao H; Xuan J; Yang M; Xu B; Wang F; Jiang M
    Metabolism; 2024 Jul; 156():155914. PubMed ID: 38642829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein.
    Morello E; Sutti S; Foglia B; Novo E; Cannito S; Bocca C; Rajsky M; Bruzzì S; Abate ML; Rosso C; Bozzola C; David E; Bugianesi E; Albano E; Parola M
    Hepatology; 2018 Jun; 67(6):2196-2214. PubMed ID: 29266399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
    Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
    J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea.
    Rey E; Del Pozo-Maroto E; Marañón P; Beeler B; García-García Y; Landete P; Isaza SC; Farré R; García-Monzón C; Almendros I; González-Rodríguez Á
    Front Med (Lausanne); 2020; 7():450. PubMed ID: 32850919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α.
    Yu L; Wang H; Han X; Liu H; Zhu D; Feng W; Wu J; Bi Y
    J Endocrinol; 2020 Jul; 246(1):57-67. PubMed ID: 32369776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [KLF9 regulates hepatic lipid metabolism via inducing CD36 expression].
    Zhou SS; Zhang YL; Chang YS
    Sheng Li Xue Bao; 2021 Oct; 73(5):772-780. PubMed ID: 34708234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cluster of Differentiation 36 Deficiency Aggravates Macrophage Infiltration and Hepatic Inflammation by Upregulating Monocyte Chemotactic Protein-1 Expression of Hepatocytes Through Histone Deacetylase 2-Dependent Pathway.
    Zhong S; Zhao L; Wang Y; Zhang C; Liu J; Wang P; Zhou W; Yang P; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
    Antioxid Redox Signal; 2017 Aug; 27(4):201-214. PubMed ID: 27967209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.
    Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J
    Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the Hypoxia Inducible Factor 1α Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones.
    Asai Y; Yamada T; Tsukita S; Takahashi K; Maekawa M; Honma M; Ikeda M; Murakami K; Munakata Y; Shirai Y; Kodama S; Sugisawa T; Chiba Y; Kondo Y; Kaneko K; Uno K; Sawada S; Imai J; Nakamura Y; Yamaguchi H; Tanaka K; Sasano H; Mano N; Ueno Y; Shimosegawa T; Katagiri H
    Gastroenterology; 2017 May; 152(6):1521-1535.e8. PubMed ID: 28088462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
    Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
    Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36.
    Zhou B; Jia L; Zhang Z; Xiang L; Yuan Y; Zheng P; Liu B; Ren X; Bian H; Xie L; Li Y; Lu J; Zhang H; Lu Y
    Adv Sci (Weinh); 2020 Nov; 7(21):2002273. PubMed ID: 33173745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.